iNOs-IN-3_product_DataBase

Bioactivity	iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 µM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research[1].
Target	IC50: 3.342 µM (iNOS)
Invitro	iNOs-IN-3 (25 μM; 24 h) inhibits LPS-induced RAW 264.7 cells[1].iNOs-IN-3 (12.5 μM; 24 h) can decrease the expression of iNOS[1]. Cell Viability Assay[1] Cell Line:
In Vivo	iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice[1].iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury[1]. Animal Model:
Name	iNOs-IN-3
CAS	2241674-94-0
Formula	C27H24N2O5S
Molar Mass	488.55
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Li Tang, et al. Design and synthesis of new disubstituted benzoxazolone derivatives that act as iNOS inhibitors with potent anti-inflammatory activity against LPS-induced acute lung injury (ALI). Bioorg Med Chem. 2020 Nov 1;28(21):115733.

PeptideDB